Correction: Effect of incorporation of pretreatment serum carcinoembryonic antigen levels into AJCC staging for colon canceron 5-year survival (JAMA Surgery (2015) 150:8 (747-755) DOI: 10.1001/jamasurg.2015.0871);Effect of incorporation of pretreatment serum carcinoembryonic antigen levels into AJCC staging for colon cancer on 5-year survival

JAMA Surgery

Volumn 150, Issue 8, 2015, Pages 747-755

  Thirunavukarasu, Pragatheeshwar ^a   Talati, Chetasi ^b   Munjal, Sumeet ^b   Attwood, Kris ^a   Edge, Stephen B ^c   Francescutti, Valerie ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c Baptist Memorial Health Care ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; COLON CANCER; COMPARATIVE STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREMEDICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; ADENOCARCINOMA; BLOOD; CANCER REGISTRY; COLON TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PREOPERATIVE PERIOD; SURVIVAL; UNITED STATES; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREOPERATIVE PERIOD; RETROSPECTIVE STUDIES; SEER PROGRAM; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84939826127     PISSN: 21686254     EISSN: 21686262     Source Type: Journal    
DOI: 10.1001/jamasurg.2019.0020     Document Type: Erratum

References (29)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
2. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Handbook. Berlin, Germany: Springer Verlag; 2010.
3. Puppa G, Sonzogni A, Colombari R, Pelosi G. TNM staging system of colorectal carcinoma: a critical appraisal of challenging issues. Arch Pathol Lab Med. 2010;134(6):837-852.
4. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010;28(2): 264-271.
5. Yarbro JW, Page DL, Fielding LP, Partridge EE, Murphy GP. American Joint Committee on Cancer prognostic factors consensus conference. Cancer. 1999;86(11):2436-2446.
6. Sobin LH. TNM: evolution and relation to other prognostic factors. Semin Surg Oncol. 2003;21(1): 3-7.
7. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer. 2000;88(7): 1739-1757.
8. Hammarström S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999;9(2):67-81.
9. Wanebo HJ, Rao B, Pinsky CM, et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med. 1978;299(9):448-451.
10. Wolmark N, Fisher B, Wieand HS, et al. The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer: results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. Ann Surg. 1984;199(4):375-382.
11. Chu DZJ, Erickson CA, Russell MP, et al. Prognostic significance of carcinoembryonic antigen in colorectal carcinoma. Serum levels before and after resection and before recurrence. Arch Surg. 1991;126(3):314-316.
12. Harrison LE, Guillem JG, Paty P, Cohen AM. Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg. 1997;185(1):55-59.
13. Lucha PA Jr, Rosen L, Olenwine JA, et al. Value of carcinoembryonic antigen monitoring in curative surgery for recurrent colorectal carcinoma. Dis Colon Rectum. 1997;40(2):145-149.
14. Moertel CG, O'Fallon JR, Go VLW, O'Connell MJ, Thynne GS. The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer. 1986;58(3): 603-610.
15. Park YJ, Park KJ, Park J-G, Lee KU, Choe KJ, Kim J-P. Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases. World J Surg. 1999;23(7):721-726.
16. Yu JB, Gross CP, Wilson LD, Smith BD. NCI SEER public-use data: applications and limitations in oncology research. Oncology (Williston Park). 2009;23(3):288-295.
17. Thirunavukarasu P, Sukumar S, Sathaiah M, et al. C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management. J Natl Cancer Inst. 2011;103(8):689-697.
18. Benson AB III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16): 3408-3419.
19. NCCN Clinical Practice Guidelines in Oncology. 3rd ed. http://www.nccn.org/professionals/physician-gls/pdf/colon.pdf. Accessed February 10, 2014.
20. O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997;15(1):246-250.
21. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol. 1999;17(5):1356-1363.
22. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22(10):1797-1806.
23. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ; Quasar Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020-2029.
24. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109-3116.
25. Ogata Y, Murakami H, Sasatomi T, et al. Elevated preoperative serum carcinoembrionic antigen level may be an effective indicator for needing adjuvant chemotherapy after potentially curative resection of stage II colon cancer. J Surg Oncol. 2009;99(1):65-70.
26. Lou Z, Meng R-G, Zhang W, Yu E-D, Fu C-G. Preoperative carcinoembryonic antibody is predictive of distant metastasis in pathologically T1 colorectal cancer after radical surgery. World J Gastroenterol. 2013;19(3):389-393.
27. Yeh C-Y, Hsieh P-S, Chiang J-M, et al. Preoperative carcinoembryonic antigen elevation in colorectal cancer. Hepatogastroenterology. 2011;58 (109):1171-1176.
28. Romanus D, Weiser MR, Skibber JM, et al. Concordance with NCCN Colorectal Cancer Guidelines and ASCO/NCCN Quality Measures: an NCCN institutional analysis. J Natl Compr Canc Netw. 2009;7(8):895-904.
29. Amri R, Bordeianou LG, Sylla P, Berger DL. Preoperative carcinoembryonic antigen as an outcome predictor in colon cancer. J Surg Oncol. 2013;108(1):14-18.